Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Long-Term Investments (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Long-Term Investments for 4 consecutive years, with $2.7 million as the latest value for Q2 2025.

  • Quarterly Long-Term Investments fell 96.33% to $2.7 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Jun 2025, down 96.33% year-over-year, with the annual reading at $30.8 million for FY2024, 65.41% down from the prior year.
  • Long-Term Investments for Q2 2025 was $2.7 million at Century Therapeutics, down from $20.7 million in the prior quarter.
  • The five-year high for Long-Term Investments was $144.6 million in Q2 2023, with the low at $2.7 million in Q2 2025.
  • Average Long-Term Investments over 4 years is $65.1 million, with a median of $54.9 million recorded in 2022.
  • The sharpest move saw Long-Term Investments soared 191.07% in 2023, then tumbled 96.33% in 2025.
  • Over 4 years, Long-Term Investments stood at $51.9 million in 2022, then skyrocketed by 71.82% to $89.1 million in 2023, then plummeted by 65.41% to $30.8 million in 2024, then plummeted by 91.27% to $2.7 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $2.7 million, $20.7 million, and $30.8 million for Q2 2025, Q1 2025, and Q4 2024 respectively.